EGFR

Where the papers sit

133 papers from the last 6 months study EGFR directly

• EGFR-Targeted Cancer Therapy

  EGFR and ErbB-directed treatment is expanding across solid tumours, from antibody blockade and photoimmunotherapy to CAR-T cells and targeted degraders. Panitumumab, amivantamab, nimotuzumab and anti-EGFR antibody-drug platforms recur alongside checkpoint inhibition and chemotherapy. Responses remain strongly dependent on tumour type, receptor expression, anatomical location and co-alterations such as SMARCA or SMARCB1 loss. The field is moving toward biomarker-selected combinations rather than uniform EGFR inhibition.

  58 papers · 43.6%

• EGFR-Mutant Lung Cancer

  Treatment of EGFR-mutant non-small cell lung cancer is consolidating around osimertinib while testing newer inhibitors, amivantamab combinations and EGFR antibody-drug conjugates. Uncommon EGFR mutations and CNS disease are driving development of selective, brain-penetrant agents such as BLU-451. Acquired resistance and drug-tolerant persister cells remain central problems, with TROP2 and ULK1 emerging as ways to delay resistance. TP53 status, EGFR amplification, VEGFA signaling and fusion events may refine prognosis and treatment selection.

  46 papers · 34.6%

• Computational EGFR Drug Discovery

  Molecular docking, dynamics, network pharmacology and QSAR are being used to prioritize natural products and designed compounds against EGFR and related targets. Recurring strategies include dual EGFR/HER-2, EGFR/tubulin and PARP-1/EGFR inhibitors, alongside computational searches for agents affecting EMT or ferroptosis. Machine learning and multi-omics increasingly supplement structure-based screening and target-network analysis. Most findings remain predictive, leaving biochemical, cellular and in vivo validation as the key unresolved step.

  29 papers · 21.8%